MedKoo Cat#: 128054 | Name: LDD 39

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LDD 39 is a RET ligand directed degrader. LDD 39 demonstrated high in vitro inhibitory and degradation potency against both RET wild-type and the two representative mutants, V804M and G810R. Importantly, in PK/PD studies, LDD 39 exhibited a differentiated and favorable in vivo profile compared to the corresponding tyrosine kinase inhibitor (TKI), compound 3. Robust and sustained degradation of total-RET (tRET) protein and inhibition of phospho-RET (pRET) signaling were observed in TPC-1 xenograft tumors driven by RET and the RET/G810R mutant following a single dose of LDD 39 at 15 and 75 mg/kg, respectively.

Chemical Structure

LDD 39
LDD 39
CAS#N/A

Theoretical Analysis

MedKoo Cat#: 128054

Name: LDD 39

CAS#: N/A

Chemical Formula: C54H57F2N11O6

Exact Mass: 993.4461

Molecular Weight: 994.12

Elemental Analysis: C, 65.24; H, 5.78; F, 3.82; N, 15.50; O, 9.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LDD 39; LDD39; LDD-39
IUPAC/Chemical Name
N-(1-(5-(3-cyano-6-ethoxypyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-4-(4-((1s,3s)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperidin-1-yl)cyclobutane-1-carbonyl)piperazin-1-yl)piperidin-4-yl)-2,5-difluorobenzamide
InChi Key
QIUWNYMIWLCOLP-DJIAWTOTSA-N
InChi Code
InChI=1S/C54H57F2N11O6/c1-2-73-41-27-42(49-38(28-57)30-59-67(49)32-41)35-5-9-47(58-29-35)63-17-13-54(14-18-63,61-50(69)44-26-39(55)6-7-45(44)56)65-21-19-64(20-22-65)52(71)37-23-40(24-37)62-15-11-33(12-16-62)34-3-4-36-31-66(53(72)43(36)25-34)46-8-10-48(68)60-51(46)70/h3-7,9,25-27,29-30,32-33,37,40,46H,2,8,10-24,31H2,1H3,(H,61,69)(H,60,68,70)/t37-,40+,46?
SMILES Code
CCOC(C=C1C2=CN=C(N3CCC(N4CCN(C([C@@H]5C[C@H](N6CCC(C7=CC=C(CN(C8C(NC(CC8)=O)=O)C9=O)C9=C7)CC6)C5)=O)CC4)(NC(C%10=C(F)C=CC(F)=C%10)=O)CC3)C=C2)=CN%11C1=C(C#N)C=N%11
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 994.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Qiao JX, Williams D, Gill P, Li L, Norris D, Tokarski JS, Wong J, Qi H, Hafeji Y, Downes DP, Degnen B, Wang YK, Locke G, Fang H, Yu F, Xu S, Naglich J, Zhang J, Nanjappa P, Dai C, Chourb L, Napoline J, Tester R, Jorge C, Li YX, Mathur A, Barbieri C, Soars MG, Venkatanarayan A, Lees E, Borzilleri RM, Gavai AV, Wichroski M, Dhar TGM. Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase. J Med Chem. 2024 Oct 22. doi: 10.1021/acs.jmedchem.4c02083. Epub ahead of print. PMID: 39437163.